Archives

Our head of Preclinical and Clinical Immunology Anna Morena D’alise will join as Expert Speaker at the Next Generation Cancer Vaccine Development Summit from September 7 – 9, 2021. You can [...]

The Next aCGT Europe Needs to Leapfrog — How? Follow the link below for more details. https://lnkd.in/dpAnmJZ  

BASEL, Switzerland – 11th March 2021: Nouscom, a clinical stage immuno-oncology biotech developing next generation viral-vector based immunotherapies, today announces it has received approval [...]

Find out more about the program and register here: Spring Private Company Showcase « Solebury Trout Access

Find out more about the program and register here: https://www.biocapitaleurope.com/programme/

BASEL, Switzerland – 11th December 2020: Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized genetic cancer vaccines, today announces that it has appointed [...]

Rick joined Nouscom in September 2020 from Johnson and Johnson Innovation where he was the Global Oncology Venture and Transaction Lead. He was Chief Executive Officer of a European clinical [...]

Göran has more than 35 years of leadership and management experience in the biotech and pharmaceutical industry, with Board positions at several global companies, including currently as Chairman [...]

Oncolytic viruses (OVs) are novel anti-tumor agents with the ability to selectively infect and kill tumor cells while sparing normal tissue. Beyond tumor cytolysis, OVs are capable of priming an [...]

ABSTRACT – Since the discovery in 1796 by Edward Jenner of vaccinia virus as a way to prevent and finally eradicate smallpox, the concept of using a virus to fight another virus has evolved [...]